摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(6-cyclopropyl-2-(4-methoxyphenyl)-3-(p-tolyl)-5H-pyrrolo[2,3-b]pyrazin-5-yl)heptanoic acid | 1447770-02-6

中文名称
——
中文别名
——
英文名称
7-(6-cyclopropyl-2-(4-methoxyphenyl)-3-(p-tolyl)-5H-pyrrolo[2,3-b]pyrazin-5-yl)heptanoic acid
英文别名
7-[6-Cyclopropyl-2-(4-methoxyphenyl)-3-(4-methylphenyl)pyrrolo[2,3-b]pyrazin-5-yl]heptanoic acid
7-(6-cyclopropyl-2-(4-methoxyphenyl)-3-(p-tolyl)-5H-pyrrolo[2,3-b]pyrazin-5-yl)heptanoic acid化学式
CAS
1447770-02-6
化学式
C30H33N3O3
mdl
——
分子量
483.61
InChiKey
VJRUTPCOZHETHV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    36
  • 可旋转键数:
    11
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    77.2
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS
    申请人:Novartis AG
    公开号:US20130184282A1
    公开(公告)日:2013-07-18
    The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    本发明提供了激活IP受体的杂环衍生物,以及制备它们的方法,包括这些衍生物的药物组合物和它们的用途。激活IP受体信号通路对治疗多种形式的PAH、肺纤维化以及在动物模型和患者中对各种器官的纤维化状况具有有益效果。
  • SUBSTITUTED PYRROLO[2,3-B]PYRAZINE COMPOUNDS AND THEIR USE
    申请人:Novartis AG
    公开号:US20150094312A1
    公开(公告)日:2015-04-02
    The present invention provides compounds of formula (Ia) and (Ib) which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said compounds and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    本发明提供了式(Ia)和(Ib)的化合物,其可以激活IP受体,制备它们的方法,包括上述化合物的制药组合物和使用方法。激活IP受体信号通路有助于治疗许多形式的PAH,肺纤维化,并在动物模型和患者中对各种器官的纤维化状况产生有益影响。
  • FUSED PYRROLES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS
    申请人:Novartis AG
    公开号:EP2802589A1
    公开(公告)日:2014-11-19
  • US8937069B2
    申请人:——
    公开号:US8937069B2
    公开(公告)日:2015-01-20
  • US9073932B2
    申请人:——
    公开号:US9073932B2
    公开(公告)日:2015-07-07
查看更多

同类化合物

S-(1-乙烯基-1H-吡唑并[3,4-b]吡嗪-5-基)乙硫酸酯 6-甲基-1H-吡唑并[3,4-b]吡嗪-3-醇 6-氯-1H-吡唑并[3,4-B]吡嗪 6-氨基-1,3-二甲基-1H-吡唑并[3,4-b]吡嗪-5-甲腈 5-甲基-1H-吡唑并[3,4-b]吡嗪-3-醇 5-溴-3-甲基-1H-吡唑并[3,4-b]吡嗪 5-溴-1H-吡唑并[3,4-b]吡嗪-3-胺 4,7-二氮杂-1H-吲唑 4,7-二氢-1H-吡唑并[3,4-b]吡嗪-5,6-二酮 3-甲基-1H-吡唑并[3,4-b]吡嗪 3-溴-1H-吡唑并[3,4-B]吡嗪 3,6-二氨基-1H-吡唑并[3,4-b]吡嗪-5-甲腈 2-(1H-吡唑并[3,4-b]吡嗪-5-基氨基)乙醇 2,3,6,7-四氢-3,6-二氧代-1H-吡唑并[3,4-b]吡嗪-5-甲腈 1H-吡唑并[3,4-B]吡嗪-3-氨基 1-甲基吡唑并[3,4-b]吡嗪-3-胺 1-甲基-1,2-二氢-3H-吡唑并[3,4-b]吡嗪-3-酮 1-(6-羟基-1,3-二甲基-1H-吡唑并[3,4-b]吡嗪-5-基)-乙酮 1-(1H-吡唑并[3,4-b]吡嗪-1-基)乙酮 1-(1,3,6-三甲基-1H-吡唑并[3,4-b]吡嗪-5-基)-乙酮 1,5,6-三甲基-1H-吡唑并[3,4-b]吡嗪 1,5,6-三甲基-1,2-二氢-3H-吡唑并[3,4-b]吡嗪-3-酮 7-(6-cyclopropyl-2-(4-methoxyphenyl)-3-(p-tolyl)-5H-pyrrolo[2,3-b]pyrazin-5-yl)heptanoic acid 7-chloro-3-(3-chloropropyl)-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 1-Methyl-pyrazolo-<3,4-b>pyrazin 5,6-Dimethyl-pyrazolo<3,4-b>pyrazin 6-(2,4-difluorophenoxymethyl)-5H-pyrrolo[2,3-b]pyrazine 2-Chloro-8-[(1S)-1-cyclopropylethyl]-6-[[[1-[(2-methoxyethyl)sulfonyl]-4-piperidinyl]methyl]amino]-7(8H)-pteridinone 5-methoxy-1H-pyrazolo[3,4-b]pyrazine 1-Ethyl-6-isopentyloxy-1H-pyrazolo[3,4-b]pyrazine-5-carbonitrile 3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1-methyl-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine N-Butyl-6-methyl-1-ethyl-1H-pyrazolo<3,4-b>pyrazine-5-carboxamid tert-butyl 6-(sec-butylamino)-3-iodoimidazo[1,2-b]pyridazin-8-yl((tetrahydro-2H-pyran-4-yl)methyl)carbamate N-Butyl-6-butylamino-1-ethyl-1H-pyrazolo<3,4-b>pyrazine-5-carboxamide 6-Hydroxy-1-ethyl-1H-pyrazolo<3,4-b>pyrazine-5-carbonitril 6-chloro-2-methyl-2H-pyrazolo[3,4-b]pyrazine 1,3,5,7-Tetramethyl-1H-pyrazolo[3,4-b][1,4]diazepin-6-one oxime 3-iodo-1-methyl-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine 6-chloro-3-iodo-1-methyl-1H-pyrazolo[3,4-b]pyrazine 1,3,5,7-Tetramethylpyrazolo<4,5-b>pyrazolo<5,4-b'>pyrazine 2,5,6-Trimethyl-pyrazolo<3,4-b>pyrazin 1,5,6-Trimethyl-1h-pyrazolo[3,4-b]pyrazin-3-amine N-(5-(difluoromethoxy)-1H-pyrazol-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazolo[3,4-b]pyrazin-6-amine 6-chloro-1-ethyl-3-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyrazine 5-bromo-1-(1-ethyl-propyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyrazine 6-chloro-1-cyclopropyl-3-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyrazine 6,7-dihydroxy-1,2-dihydro-pyrazolo[3,4-b]quinoxaline-3,5,8-trione ethyl 6-chloro-1-methyl-1H-pyrazolo[3,4-b]pyrazine-3-carboxylate 1-methyl-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine-3-carboxylic acid 1-(1-ethyl-propyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyrazine